Keros Therapeutics, Inc.
NASDAQ:KROS
16.81 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Keros Therapeutics, Inc. |
Symbool | KROS |
Munteenheid | USD |
Prijs | 16.81 |
Beurswaarde | 680,929,394 |
Dividendpercentage | 0% |
52-weken bereik | 15.67 - 73 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jasbir S. Seehra Ph.D. |
Website | https://www.kerostx.com |
An error occurred while fetching data.
Over Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)